Selecting patients for cytotoxic therapies in gastroenteropancreatic neuroendocrine tumours

Best Practice and Research: Clinical Gastroenterology

Volumn 26, Issue 6, 2012, Pages 843-854

  Costa, F P ^a   Gumz, B ^a   Pasche, B ^b  

^a HOSPITAL SÍRIO LIBANÊS   (Brazil)

^b University of Alabama at Birmingham   (United States)

Author keywords

Carcinoid; Chemotherapy; Gastroenteropancreatic; Neuroendocrine tumour; Pancreatic

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; PACLITAXEL; STREPTOZOCIN; SUNITINIB; TEMOZOLOMIDE; THALIDOMIDE; VALPROIC ACID;

APPENDIX CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER PALLIATIVE THERAPY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CARCINOID; CECUM CANCER; COLON CANCER; CYTOREDUCTIVE SURGERY; DRUG INDICATION; DUODENUM CANCER; HUMAN; IMMUNOHISTOCHEMISTRY; MEDICAL DECISION MAKING; METASTASIS; MIDGUT; OVERALL SURVIVAL; PANCREAS CANCER; PANCREATIC NEUROENDOCRINE TUMOR; PATIENT SELECTION; PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIMARY TUMOR; PROGRESSION FREE SURVIVAL; RECTUM CANCER; SMALL INTESTINE CANCER; STOMACH CANCER; SYSTEMIC THERAPY; TREATMENT DURATION; TUMOR DIFFERENTIATION;

EID: 84876150242     PISSN: 15216918     EISSN: 15321916     Source Type: Journal    
DOI: 10.1016/j.bpg.2012.12.001     Document Type: Review

References (84)

1. J.C. Yao, M. Hassan, and A. Phan One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States Journal of Clinical Oncology 26 2008 3063 3072
2. I.M. Modlin, K.D. Lye, and M.A. Kidd 5-decade analysis of 13,715 carcinoid tumors Cancer 97 2003 934 959
3. E.T. Janson, and K. Oberg Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon Acta Oncologica 32 1993 225 229
4. J.C. Yao, M.P. Eisner, and C. Leary Population-based study of islet cell carcinoma Annals of Surgical Oncology 14 2007 3492 3500
5. A. Zerbi, M. Falconi, and G. Rindi Clinicopathological features of pancreatic endocrine tumors: a prospective multicenter study in Italy of 297 sporadic cases The American Journal of Gastroenterology. 105 2010 1421 1429
6. F. Ehehalt, H.D. Saeger, C.M. Schmidt, and R. Grutzmann Neuroendocrine tumors of the pancreas The Oncologist 14 2009 456 467
7. B. Hirshberg, C. Cochran, and M.C. Skarulis Malignant insulinoma: spectrum of unusual clinical features Cancer 104 2005 264 272
8. M.H. Kulke, J. Bendell, L. Kvols, J. Picus, R. Pommier, and J. Yao Evolving diagnostic and treatment strategies for pancreatic neuroendocrine tumors Journal of Hematology & Oncology 4 2011 29
9. A. Ganetsky, and V. Bhatt Gastroenteropancreatic neuroendocrine tumors: update on therapeutics The Annals of Pharmacotherapy 46 2012 851 862
10. E. Vilar, R. Salazar, J. Perez-Garcia, J. Cortes, K. Oberg, and J. Tabernero Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors Endocrine-related Cancer 14 2007 221 232
11. B. Basu, B. Sirohi, and P. Corrie Systemic therapy for neuroendocrine tumours of gastroenteropancreatic origin Endocrine-related Cancer 17 2010 R75 R90
12. F. Costa, E. Domenichini, and G. Garavito Management of neuroendocrine tumors: a meeting of experts from Latin America Neuroendocrinology 88 2008 235 242
13. J.R. Strosberg, A. Cheema, and L.K. Kvols A review of systemic and liver-directed therapies for metastatic neuroendocrine tumors of the gastroenteropancreatic tract Cancer Control: Journal of the Moffitt Cancer Center. 18 2011 127 137
14. B. Lawrence, B.I. Gustafsson, M. Kidd, and I. Modlin New pharmacologic therapies for gastroenteropancreatic neuroendocrine tumors Gastroenterology Clinics of North America. 39 2010 615 628
15. A.S. Paulson, and E.K. Bergsland Systemic therapy for advanced carcinoid tumors: where do we go from here? Journal of the National Comprehensive Cancer Network. 10 2012 785 793
16. G. Poncet, J.L. Faucheron, and T. Walter Recent trends in the treatment of well-differentiated endocrine carcinoma of the small bowel World Journal of Gastroenterology 16 2010 1696 1706
17. O. Norlen, P. Stalberg, and K. Oberg Long-term results of surgery for small intestinal neuroendocrine tumors at a tertiary referral center World Journal of Surgery 36 2012 1419 1431
18. A. Zerbi, V. Capitanio, and L. Boninsegna Surgical treatment of pancreatic endocrine tumours in Italy: results of a prospective multicentre study of 262 cases Langenbeck's Archives of Surgery/Deutsche Gesellschaft Fur Chirurgie 396 2011 313 321
19. S. Ekeblad, B. Skogseid, K. Dunder, K. Oberg, and B. Eriksson Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution Clinical Cancer Research 14 2008 7798 7803
20. E.S. Glazer, J.F. Tseng, and W. Al-Refaie Long-term survival after surgical management of neuroendocrine hepatic metastases HPB 12 2010 427 433
21. M.H. Kulke, L.L. Siu, and J.E. Tepper Future directions in the treatment of neuroendocrine tumors: consensus report of the national cancer institute neuroendocrine tumor clinical trials planning meeting Journal of Clinical Oncology 29 2011 934 943
22. D. O'Toole, O. Hentic, O. Corcos, and P. Ruszniewski Chemotherapy for gastro-enteropancreatic endocrine tumours Neuroendocrinology 80 Suppl. 1 2004 79 84
23. H. Sorbye, S. Welin, and S.W. Langer Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study Annals of Oncology Sep 11 2012
24. E.D. Williams, and M. Sandler The classification of carcinoid tumours Lancet 1 1963 238 239
25. B. Estrozi, and C.E. Bacchi Neuroendocrine tumors involving the gastroenteropancreatic tract: a clinicopathological evaluation of 773 cases Clinics (Sao Paulo) 66 2011 1671 1675
26. P.F. Engstrom, P.T. Lavin, C.G. Moertel, E. Folsch, and H.O. Douglass Jr. Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor Journal of Clinical Oncology 2 1984 1255 1259
27. C.G. Moertel, J.A. Hanley, and L.A. Johnson Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma The New England Journal of Medicine 303 1980 1189 1194
28. C.G. Moertel, M. Lefkopoulo, S. Lipsitz, R.G. Hahn, and D. Klaassen Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma The New England Journal of Medicine 326 1992 519 523
29. K. Oberg, I. Norheim, G. Lundqvist, and L. Wide Cytotoxic treatment in patients with malignant carcinoid tumors. Response to streptozocin-alone or in combination with 5-FU Acta Oncologica 26 1987 429 432
30. E.T. Janson, L. Ronnblom, and H. Ahlstrom Treatment with alpha-interferon versus alpha-interferon in combination with streptozocin and doxorubicin in patients with malignant carcinoid tumors: a randomized trial Annals of Oncology 3 1992 635 638
31. R.M. Bukowski, C.M. Tangen, and R.F. Peterson Phase II trial of dimethyltriazenoimidazole carboxamide in patients with metastatic carcinoid. A Southwest Oncology Group study Cancer 73 1994 1505 1508
32. M. Di Bartolomeo, E. Bajetta, and A.M. Bochicchio A phase II trial of dacarbazine, fluorouracil and epirubicin in patients with neuroendocrine tumours. A study by the Italian Trials in Medical Oncology (I.T.M.O.) Group Annals of Oncology 6 1995 77 79
33. R.M. Bukowski, K.G. Johnson, and R.F. Peterson A phase II trial of combination chemotherapy in patients with metastatic carcinoid tumors. A Southwest Oncology Group Study Cancer 60 1987 2891 2895
34. T. Walter, D. Bruneton, and P.A. Cassier Evaluation of the combination 5-fluorouracil, dacarbazine, and epirubicin in patients with advanced well-differentiated neuroendocrine tumors Clinical Colorectal Cancer 9 2010 248 254
35. M.H. Kulke, K. Stuart, and P.C. Enzinger Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors Journal of Clinical Oncology 24 2006 401 406
36. M.H. Kulke, H. Kim, and J.W. Clark A phase II trial of gemcitabine for metastatic neuroendocrine tumors Cancer 101 2004 934 939
37. M.H. Kulke, H. Kim, and K. Stuart A phase II study of docetaxel in patients with metastatic carcinoid tumors Cancer Investigation 22 2004 353 359
38. S.M. Ansell, H.C. Pitot, P.A. Burch, L.K. Kvols, M.R. Mahoney, and J. Rubin A phase II study of high-dose paclitaxel in patients with advanced neuroendocrine tumors Cancer 91 2001 1543 1548
39. E. Bajetta, L. Rimassa, and C. Carnaghi 5-Fluorouracil, dacarbazine, and epirubicin in the treatment of patients with neuroendocrine tumors Cancer 83 1998 372 378
40. S. Ollivier, M. Fonck, Y. Becouarn, and R. Brunet Dacarbazine, fluorouracil, and leucovorin in patients with advanced neuroendocrine tumors: a phase II trial American Journal of Clinical Oncology 21 1998 237 240
41. W. Sun, S. Lipsitz, P. Catalano, J.A. Mailliard, and D.G. Haller Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281 Journal of Clinical Oncology 23 2005 4897 4904
42. A.A. Mohammed, J. Karasiewicz, and J.A. Modlinski Developmental potential of selectively enucleated immature mouse oocytes upon nuclear transfer Molecular Reproduction and Development 75 2008 1269 1280
43. B. Wiedenmann, M. Pavel, and B. Kos-Kudla From targets to treatments: a review of molecular targets in pancreatic neuroendocrine tumors Neuroendocrinology 94 2011 177 190
44. I.M. Modlin, M. Pavel, M. Kidd, and B.I. Gustafsson Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours Alimentary Pharmacology & Therapeutics 31 2010 169 188
45. R.M. Bukowski, C. Tangen, and R. Lee Phase II trial of chlorozotocin and fluorouracil in islet cell carcinoma: a Southwest Oncology Group study Journal of Clinical Oncology 10 1992 1914 1918
46. A.D. McCollum, M.H. Kulke, and D.P. Ryan Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic endocrine tumors American Journal of Clinical Oncology 27 2004 485 488
47. P.N. Cheng, and L.B. Saltz Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma Cancer 86 1999 944 948
48. R.K. Ramanathan, A. Cnaan, R.G. Hahn, P.P. Carbone, and D.G. Haller Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282 Annals of Oncology 12 2001 1139 1143
49. N.C. Turner, S.J. Strauss, and D. Sarker Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours British Journal of Cancer 102 2010 1106 1112
50. M.A. Kouvaraki, J.A. Ajani, and P. Hoff Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas Journal of Clinical Oncology 22 2004 4762 4771
51. S. Ekeblad, A. Sundin, and E.T. Janson Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors Clinical Cancer Research 13 2007 2986 2991
52. J.R. Strosberg, R.L. Fine, and J. Choi First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas Cancer 117 2011 268 275
53. S.M. Ansell, M.R. Mahoney, E.M. Green, and J. Rubin Topotecan in patients with advanced neuroendocrine tumors: a phase II study with significant hematologic toxicity American Journal of Clinical Oncology 27 2004 232 235
54. I.H. Olsen, J.B. Sorensen, and B. Federspiel Temozolomide as second or third line treatment of patients with neuroendocrine carcinomas The Scientific World Journal 2012 2012 170496
55. J. Murakami, Y.J. Lee, and S. Kokeguchi Depletion of O6-methylguanine-DNA methyltransferase by O6-benzylguanine enhances 5-FU cytotoxicity in colon and oral cancer cell lines Oncology Reports 17 2007 1461 1467
56. M.H. Kulke, J.L. Hornick, and C. Frauenhoffer O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors Clinical Cancer Research 15 2009 338 345
57. E. Bajetta, L. Catena, and G. Procopio Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours? Cancer Chemotherapy and Pharmacology 59 2007 637 642
58. P.A. Cassier, T. Walter, and B. Eymard Gemcitabine and oxaliplatin combination chemotherapy for metastatic well-differentiated neuroendocrine carcinomas: a single-center experience Cancer 115 2009 3392 3399
59. O. Hentic, P. Hammel, and A. Couvelard FOLFIRI regimen: an effective second-line chemotherapy after failure of etoposide-platinum combination in patients with neuroendocrine carcinomas grade 3 Endocrine-related Cancer 19 2012 751 757
60. K. Nakano, S. Takahashi, and T. Yuasa Feasibility and efficacy of combined cisplatin and irinotecan chemotherapy for poorly differentiated neuroendocrine carcinomas Japanese Journal of Clinical Oncology 42 2012 697 703
61. H. Brixi-Benmansour, J.L. Jouve, and E. Mitry Phase II study of first-line FOLFIRI for progressive metastatic well-differentiated pancreatic endocrine carcinoma Digestive and Liver Disease 43 2011 912 916
62. J.C. Yao, M.H. Shah, and T. Ito Everolimus for advanced pancreatic neuroendocrine tumors The New England Journal of Medicine 364 2011 514 523
63. M.E. Pavel, J.D. Hainsworth, and E. Baudin Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study Lancet 378 2011 2005 2012
64. E. Raymond, L. Dahan, and J.L. Raoul Sunitinib malate for the treatment of pancreatic neuroendocrine tumors The New England Journal of Medicine 364 2011 501 513
65. C.A. Moran, S. Suster, D. Coppola, and M.R. Wick Neuroendocrine carcinomas of the lung: a critical analysis American Journal of Clinical Pathology 131 2009 206 221
66. G. Rindi The ENETS guidelines: the new TNM classification system Tumori 96 2010 806 809
67. A. Scarpa, W. Mantovani, and P. Capelli Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients Modern Pathology 23 2010 824 833
68. J.R. Strosberg, D. Coppola, and D.S. Klimstra The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas Pancreas 39 2010 799 800
69. C.G. Moertel, L.K. Kvols, M.J. O'Connell, and J. Rubin Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms Cancer 68 1991 227 232
70. E. Mitry, E. Baudin, and M. Ducreux Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin British Journal of Cancer 81 1999 1351 1355
71. M.L. Fjallskog, D.P. Granberg, and S.L. Welin Treatment with cisplatin and etoposide in patients with neuroendocrine tumors Cancer 92 2001 1101 1107
72. J.D. Hainsworth, D.R. Spigel, S. Litchy, and F.A. Greco Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network Study Journal of Clinical Oncology 24 2006 3548 3554
73. B. Brenner, M.A. Shah, M. Gonen, D.S. Klimstra, J. Shia, and D.P. Kelsen Small-cell carcinoma of the gastrointestinal tract: a retrospective study of 64 cases British Journal of Cancer 90 2004 1720 1726
74. D.S. Klimstra, I.R. Modlin, and N.V. Adsay Pathology reporting of neuroendocrine tumors: application of the delphic consensus process to the development of a minimum pathology data set The American Journal of Surgical Pathology 34 2010 300 313
75. D.S. Klimstra, I.R. Modlin, D. Coppola, R.V. Lloyd, and S. Suster The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems Pancreas 39 2010 707 712
76. L. Sun, S. Sakurai, T. Sano, M. Hironaka, O. Kawashima, and T. Nakajima High-grade neuroendocrine carcinoma of the lung: comparative clinicopathological study of large cell neuroendocrine carcinoma and small cell lung carcinoma Pathology International 59 2009 522 529
77. K. Hiroshima, A. Iyoda, and T. Shida Distinction of pulmonary large cell neuroendocrine carcinoma from small cell lung carcinoma: a morphological, immunohistochemical, and molecular analysis Modern Pathology 19 2006 1358 1368
78. O. Nilsson, E. Van Cutsem, and G. Delle Fave Poorly differentiated carcinomas of the foregut (gastric, duodenal and pancreatic) Neuroendocrinology 84 2006 212 215
79. A. Rinke, H.H. Muller, and C. Schade-Brittinger Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group Journal of Clinical Oncology 27 2009 4656 4663
80. J. Rothenstein, S.P. Cleary, and G.R. Pond Neuroendocrine tumors of the gastrointestinal tract: a decade of experience at the Princess Margaret Hospital American Journal of Clinical Oncology 31 2008 64 70
81. F. Sellner, S. Thalhammer, S. Stattner, J. Karner, and M. Klimpfinger TNM stage and grade in predicting the prognosis of operated, non-functioning neuroendocrine carcinoma of the pancreas-a single-institution experience Journal of Surgical Oncology 104 2011 17 21
82. A. von Herbay, B. Sieg, G. Schurmann, W.J. Hofmann, M. Betzler, and H.F. Otto Proliferative activity of neuroendocrine tumours of the gastroenteropancreatic endocrine system: DNA flow cytometric and immunohistological investigations Gut 32 1991 949 953
83. U.F. Pape, H. Jann, and J. Muller-Nordhorn Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors Cancer 113 2008 256 265
84. G. Rindi, G. Kloppel, and H. Alhman TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system Virchows Archiv 449 2006 395 401